Overactive Bladder - Results from #320

A multicenter cross-sectional study on the prevalence of overactive bladder and its impacts on the quality of life in gynecologic outpatients. March 29, 2020

The effect of a sharp increase in estrogen levels on OVERACTIVE BLADDER symptoms in women undergoing ovulation induction. March 29, 2020

The association between serum serotonin levels and overactive bladder: results from a community-based cross-sectional study in Japan. March 29, 2020

The Pharmacological Mechanism of Diabetes Mellitus-Associated Overactive Bladder and Its Treatment with Botulinum Toxin A. March 29, 2020

NO-releasing nanoparticles ameliorate detrusor overactivity in transgenic sickle cell mice via restored NO/ROCK signaling. March 29, 2020

Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR). March 23, 2020

A pilot study to investigate the associations of urinary concentrations of urinary NO, ATP and derivatives with overactive bladder symptom severity. March 23, 2020

Quality of life and treatment persistence evaluation in Spanish patients treated with mirabegron. Results of the BELIEVE study. March 23, 2020

Effects of Treating an Overactive Urinary Bladder in Patients with Multiple Sclerosis. March 23, 2020

Transcutaneous Electrical Spinal Cord Neuromodulator (TESCoN) Improves Symptoms of Overactive Bladder. March 16, 2020

International Phase III, Randomized, Double-Blind, Placebo- and Active-Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR. March 15, 2020

Combination drug therapy against OAB normalizes micturition parameters and increases the release of nitric oxide during chemically induced cystitis. March 15, 2020

New Clinical Trial Examines a Potential Noninvasive Solution for Overactive Bladders March 11, 2020

Urovant Sciences Announces U.S. FDA Acceptance of New Drug Application for Vibegron for the Treatment of Overactive Bladder March 10, 2020

8 versus 12 weeks of percutaneous tibial nerve stimulation and response predictors for overactive bladder. March 9, 2020

Efficacy of vibegron, a novel β3-adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo-controlled, double-blind, comparative phase 3 study. March 8, 2020

Italian real-life clinical setting: the persistence and adherence with mirabegron in women with overactive bladder. March 3, 2020

Comparing the Efficacy of OnabotulinumtoxinA, Sacral Neuromodulation, and Peripheral Tibial Nerve Stimulation as Third Line Treatment for the Management of Overactive Bladder Symptoms in Adults: Systematic Review and Network Meta-Analysis. March 1, 2020

Current management of refractory overactive bladder. February 24, 2020

New participant stratification and combination of urinary biomarkers and confounders could improve diagnostic accuracy for overactive bladder. February 23, 2020

Page 17 of 101

email news signup